Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
StockNews.AI · 3 hours
AI Summary
Addex reported Q1 2026 results, noting Neurosterix progress toward a July Phase 1 readout for NTX-253, an M4 PAM for schizophrenia. Cash and equivalents fell to CHF 0.9 million as operating losses persisted, while R&D spend decreased and G&A declined. Data timing and funding needs will likely drive near-term shares.
Sentiment Rationale
The results show cash burn and a near-term data catalyst; neither clearly positive nor negative for ADXN without data readout or financing news. Historically, small-cap biotech stocks react modestly unless data is strong or financing is announced; near-term risk is funding balance while upside hinges on NTX-253 data outcome.
Trading Thesis
Near-term ADXN moves hinge on NTX-253 Phase 1 data in July; positive data could spark a rally.
Market-Moving
- NTX-253 Phase 1 data due in July could catalyze ADXN.
- Cash runway under CHF 1m may pressure near-term dilution or financing.
- Spin-out Neurosterix progress supports long-term value but not immediate cash flow.
- Indivior collaboration context adds sentiment but unclear near-term impact.
Key Facts
- Addex reports Q1 2026 results and corporate update. Spin-out Neurosterix advances through Phase 1.
- NTX-253 Phase 1 data expected July. Potential schizophrenia signal under evaluation.
- Q1 cash at CHF 0.9m. Net loss CHF 1.7m.
- Revenue CHF 8k; R&D nearly nil; G&A down.
- July data and financing updates may move ADXN.
Companies Mentioned
- Addex Therapeutics (ADXN): Publishes Q1 results; NTX-253 and Neurosterix updates are near-term catalysts.
- Neurosterix US Holdings LLC (Private): Spin-out progressing in Phase 1; NTX-253 data due July; potential value creator.
- Indivior (INDV): Partner; GABAB PAM program collaboration referenced; potential downstream implications.
- Stalicla (Private): Addex has invested; private company in precision neurodevelopmental medicine; indirect impact.
Earnings
Category fits Earnings and Corporate Developments for a clinical-stage biotech; catalyst timing (NTX-253 July data) and financing dynamics are key drivers of near-term sentiment.